Major Lab Publications

  1. Yosef N, Xia RH, Ubogu EE. Development and characterization of a novel human in vitro blood-nerve barrier model using primary endoneurial endothelial cells. Journal of Neuropathology and Experimental Neurology 2010; 69:82-97 (DOI: 10.1097/NEN/0b013e3181c84a9).
  2. Yosef N, Ubogu EE. GDNF restores human blood-nerve barrier function via RET tyrosine kinase-mediated cytoskeletal reorganization. Microvascular Research 2012; 83:298-310 (DOI: 10.1016/j.mvr.2012.01.005).
  3. Yosef N, Ubogu EE. αMβ2-integrin-intercellular adhesion molecule-1 interactions drive the flow-dependent trafficking of Guillain-Barré syndrome patient derived mononuclear leukocytes at the blood-nerve barrier in vitro. Journal of Cellular Physiology 2012; 227:3857-3875 (DOI: 10.1002/jcp.24100).
  4. Yosef N, Ubogu EE. An immortalized human blood-nerve barrier endothelial cell line for in vitro permeability studies. Cellular and Molecular Neurobiology 2013; 33:175-186 (DOI: 10.1007/s10571-012-9882-7).
  5. Ubogu EE. The molecular and biophysical characterization of the human blood-nerve barrier: Current concepts. Journal of Vascular Research 2013; 50:289-303 (DOI: 10.1159/000353293).
  6. Lakshmana Reddy C, Yosef N, Ubogu EE. VEGF-A165 potently induces human blood-nerve barrier endothelial cell proliferation, angiogenesis and wound healing in vitro. Cellular and Molecular Neurobiology 2013; 33:789-801 (DOI: 10.1007/s10571-013-9946-3).
  7. Yuan F, Yosef N, Lakshmana Reddy C, Huang A, Chiang SC, Rahman Tithi H, Ubogu EE. CCR2 gene deletion and pharmacologic blockade ameliorate a severe murine experimental autoimmune neuritis model of Guillain-Barré syndrome. PLOS One 2014;9: e90463 (DOI: 10.1371/journal.pone.0090463).
  8. Ubogu EE. Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention. Acta Neuropathologica 2015; 130:445-468 (DOI: 10.1007/s00401-015-1466-4).
  9. Dong C, Palladino SP, Helton ES, Ubogu EE. The pathogenic relevance of αM-integrin in Guillain-Barré syndrome. Acta Neuropathologica 2016; 132: 739-752 (DOI: 10.1007/s00401-016-1599-0).
  10. Helton ES, Palladino SP, Ubogu EE. A novel method for measuring hydraulic conductivity at the human blood-nerve barrier in vitro. Microvascular Research 2017; 109:1-6 (DOI: 10.1016/j.mvr.2016.08.005).
  11. Dong C, Greathouse KM, Beacham RL, Palladino SP, Helton ES, Ubogu EE. Fibronectin connecting segment-1 peptide inhibits pathogenic leukocyte trafficking and inflammatory demyelination in experimental models of chronic inflammatory demyelinating polyradiculoneuropathy. Experimental Neurology 2017; 292: 35-45 (DOI: 10.1016/j.expneurol.2017.02.012).
  12. Palladino SP, Helton ES, Jain P, Dong C, Crowley MR, Crossman DK, Ubogu EE. The human blood-nerve barrier transcriptome. Scientific Reports 2017; 7: 17477 (DOI: 10.1038/s41598-017-17475-y). Springer Nature SharedIt link
  13. Dong C, Helton ES, Zhou P, Ouyang X, d’Anglemont de Tassigny X, Pascual A, López-Barneo J, Ubogu EE. Glial-derived neurotrophic factor is essential for blood-nerve barrier functional recovery in an experimental murine model of traumatic peripheral neuropathy. Tissue Barriers 2018; 6 (2):1-22 (DOI: 10.1080/21688370.2018.1479570).
  14. Dong C, Ubogu EE. GDNF enhances human blood-nerve barrier function in vitro via MAPK signaling pathways. Tissue Barriers 2018; 6 (4),1-22 (DOI: 10.1080/21688370.2018.1546537).
  15. Ubogu EE. Biology of the human blood-nerve barrier in health and disease. Special Issue: Blood-CNS and blood-nerve barriers in health and diseases and potential therapy (Guest editors: Lee, J-P and Sheikh, K). Experimental Neurology 2020; 328: 113272 (DOI: 10.1016/j.expneurol.2020.113272).